We first identified breast cancer cell lines mimicking in vitro the drug-induced activation of the IFN/STAT1 signature observed in vivo, then we used these models to decipher both the upstream mechanisms and downstream consequences of this IFN/STAT1 fingerprint. This evidence concerns the gene STAT1 and breast carcinoma.